Corcept Therapeutics Incorporated (CORT) financial statements and ratios from SEC XBRL: revenue $0.8B (TTM), net margin 13.1%, revenue growth 12.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $761.41M |
| Revenue (TTM) | $0.8B |
| Net Margin | 13.1% |
| Operating Margin (TTM) | -5.6% |
| Revenue Growth (YoY) | 12.8% |
| EPS Growth (YoY) | -29.6% |
| FCF Growth (YoY) | -27.6% |
| Price / Book | 18.72 |
| Price / Sales | 16.65 |
| FCF Yield | 0.6% |
| Altman Z-Score | 43.94 (safe) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
CORT overview · CORT earnings · CORT KPIs · CORT documents · CORT ownership · CORT peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.